<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38183" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dexrazoxane</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Eneh</surname>
            <given-names>Chiamaka</given-names>
          </name>
          <aff>All Saints University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lekkala</surname>
            <given-names>Manidhar Reddy</given-names>
          </name>
          <aff>University of Rochester Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chiamaka Eneh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manidhar Reddy Lekkala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38183.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Dexrazoxane is a medication used in the management and treatment of anthracycline-induced cardiotoxicity and extravasation injuries. It is in the class of medications known as cardioprotectants. This activity reviews the indications, action, and contraindications for dexrazoxane as a valuable agent in the management of cardiotoxicity and anthracycline extravasation leading to tissue damage. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the care of patients with anthracycline-induced cardiotoxicity, extravasation injuries and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of dexrazoxane.</p></list-item><list-item><p>Review the administration of dexrazoxane including dosage adjustments in renal and hepatic impaired patients.</p></list-item><list-item><p>Identify the adverse effects seen with dexrazoxane use along with the protocols in place as regards to the toxicity of this drug.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team to enhance care delivery for patients receiving dexrazoxane.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38183&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38183">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38183.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Dexrazoxane, an FDA-approved cardioprotective drug, has been successfully used to ameliorate&#x000a0;cardiac toxicity seen in anthracycline-based (e.g., doxorubicin, daunorubicin, epirubicin) chemotherapy recipients for cancer, mainly in advanced breast cancer patients, adult patients with soft tissue sarcomas, or small-cell lung cancer.<xref ref-type="bibr" rid="article-38183.r1">[1]</xref><xref ref-type="bibr" rid="article-38183.r2">[2]</xref>&#x000a0;It&#x000a0;is used intravenously in conjunction with the anthracycline of choice to decrease the incidence of cardiomyopathy and congestive heart failure.<xref ref-type="bibr" rid="article-38183.r3">[3]</xref>&#x000a0;</p>
        <p>Dexrazoxane has also shown an indication in the&#x000a0;prevention of surrounding tissue damage&#x000a0;caused by extravasation of anthracyclines, which can occur upon administration of these&#x000a0;chemotherapeutic drugs.<xref ref-type="bibr" rid="article-38183.r4">[4]</xref></p>
        <p>However, dexrazoxane&#x000a0;treatment does not completely eliminate the risk of cardiac toxicity induced by anthracyclines, so it is necessary to check on the patient&#x02019;s cardiac function before and consistently during therapy to analyze the left ventricular ejection fraction (LVEF).</p>
        <p>
<bold>FDA-approved indications:</bold>
</p>
        <p>1. Reduction of incidence and severity of cardiac dysfunction associated with anthracycline&#x000a0;use.</p>
        <p>2. Dexrazoxane can also be used to treat tissue damage caused by anthracyclines when they leak from the vein while being administered.</p>
        <p>
<bold>Non-FDA-approved indication:</bold>
</p>
        <p>Although a study is still underway as of this writing, dexrazoxane may act as a&#x000a0;beneficial&#x000a0;neuroprotectant to treat neurodegeneration in patients with Parkinson's disease.<xref ref-type="bibr" rid="article-38183.r5">[5]</xref></p>
      </sec>
      <sec id="article-38183.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Anthracyclines are known&#x000a0;to&#x000a0;potentiate cytotoxic effects via&#x000a0;different mechanisms, which include intercalating into nuclear DNA, the creation of reactive oxygen species, and inducing apoptosis or cell death.</p>
        <p>Dexrazoxane appears to ameliorate the cardiotoxicity seen with anthracyclines by fusing with free and bound iron, thereby decreasing the formation of anthracycline-iron complexes and, eventually, the production of reactive oxygen species, which are harmful to the surrounding cardiac tissue.<xref ref-type="bibr" rid="article-38183.r1">[1]</xref>&#x000a0;</p>
        <p>Dexrazoxane is known to be from the family of compounds known as bisdioxopiperazine. Unlike its iron-chelating analog ethylenediaminetetraacetic acid (EDTA), dexrazoxane is ring-enclosed and hydrophilic. However, unlike EDTA, it&#x000a0;diffuses into cells readily. Upon its chemical breakdown, dexrazoxane transforms&#x000a0;into a form similar to EDTA, a potent iron chelator; this, consequently, displaces excess iron from the anthracycline thought to be liable, in part, for the cardiomyopathy seen with anthracyclines.<xref ref-type="bibr" rid="article-38183.r6">[6]</xref></p>
        <p>Dexrazoxane also acts as a DNA topoisomerase II inhibitor,&#x000a0;which happens to be the same target of the DNA topoisomerase II anti-cancer agent (e.g., the anthracyclines),&#x000a0;antagonizing the formation of the topoisomerase II cleavage complex and also rapidly degrading topoisomerase II beta.<xref ref-type="bibr" rid="article-38183.r7">[7]</xref></p>
        <p>Dexrazoxane, however, does not induce harmful breaks in the double-strands of DNA as the anthracyclines.<xref ref-type="bibr" rid="article-38183.r8">[8]</xref>&#x000a0;</p>
        <p>Dexrazoxane was also found to enhance the viability of cells and impose cardiac&#x000a0;function protection by attenuating the apoptosis of cardiomyocytes and necroptosis simultaneously after treatment with doxorubicin via&#x000a0;interference of the p38MAPK/NF-&#x003ba;B pathways.<xref ref-type="bibr" rid="article-38183.r9">[9]</xref></p>
      </sec>
      <sec id="article-38183.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The drug's administration is usually via intravenous infusion over 15 minutes. It is not recommended&#x000a0;as&#x000a0;a push.</p>
        <p>The suggested dosage ratio of dexrazoxane&#x000a0;to doxorubicin is 10&#x000a0;to 1 (eg, 500 mg/m<sup>2</sup> dexrazoxane&#x000a0;to 50 mg/m<sup>2</sup> doxorubicin). It is advisable to&#x000a0;give dexrazoxane before doxorubicin. Administration of doxorubicin within half an hour after the completion of dexrazoxane&#x000a0;infusion is recommended.</p>
        <p>Administer the diluted solution of dexrazoxane in lactated Ringer's solution intravenously over a quarter of an hour (15 minutes) before doxorubicin. Doxorubicin is usually infused approximately 30 minutes after dexrazoxane. It is not advisable to use dexrazoxane with a non-anthracycline chemotherapy regimen.</p>
        <p>For extravasation treatment, the proposed dosage and rate is 1,000 mg/m<sup>2</sup> IV within 6 hours post extravasation given over 1 to 2 hours in a different large vein. This administration is then followed with doses of 1,000 mg/m<sup>2</sup> and 500 mg/m<sup>2</sup> after 2 and 3 days, respectively.</p>
        <p>The dosing mechanism differs in people with renal or hepatic impairment.&#x000a0;</p>
        <p>
<bold>Dosing in Renal Impaired Patients</bold>
</p>
        <p>The dose of dexrazoxane requires a reduction in patients who have moderate to significant renal impairment (eg, creatinine clearance lower than 40 mL/min) by 50%, i.e., dexrazoxane to doxorubicin ratio reduced to 5&#x000a0;to 1 (eg, 200 mg/m<sup>2</sup> dexrazoxane: 40 mg/m<sup>2</sup> doxorubicin).</p>
        <p>
<bold>Dosing in Hepatic Impairment</bold>
</p>
        <p>In a patient with hyperbilirubinemia,&#x000a0;it is necessary to decrease the dosage of doxorubicin, leading to a subsequent dosage reduction of dexrazoxane in this group of patients while still maintaining the 10&#x000a0;to 1 ratio.</p>
        <p>Dexrazoxane is recommended for use&#x000a0;only in patients who have been administered an increasing doxorubicin dose of 300 mg/m<sup>2</sup> or doses of epirubicin &#x0003e;550 mg/m<sup>2</sup> and are continuing with anthracycline&#x000a0;therapy.<xref ref-type="bibr" rid="article-38183.r10">[10]</xref></p>
      </sec>
      <sec id="article-38183.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The common side effects that culminate from dexrazoxane use include&#x000a0;dose-limiting myelotoxicity (neutropenia, leukopenia, granulocytopenia, and thrombocytopenia), which is&#x000a0;very similar to the side-effect profile of anthracyclines. It is, therefore, challenging to distinguish the adverse effects seen with dexrazoxane use from those of anthracycline chemotherapy. Other adverse effects include&#x000a0;nausea/vomiting, increased renal excretion of iron and zinc, hair loss, mucositis, inconsistent increases in liver enzymes (alanine aminotransferase/aspartate aminotransferase),&#x000a0;reactions at the injection site such as pain, superficial phlebitis, which led to the recommendation that&#x000a0;dexrazoxane should be&#x000a0;administered&#x000a0;via a large vein.<xref ref-type="bibr" rid="article-38183.r4">[4]</xref><xref ref-type="bibr" rid="article-38183.r11">[11]</xref><xref ref-type="bibr" rid="article-38183.r12">[12]</xref>&#x000a0;Embryo-fetal toxicity and male infertility were also noted in studies conducted on mice.</p>
        <p>Recently, there have been concerns about the risk, particularly in pediatric patients, with long-term effects of dexrazoxane, who continuously received&#x000a0;doses to inhibit&#x000a0;cardiotoxicity. Although very sporadic, the incidence of other&#x000a0;primary malignancies (myelodysplastic syndrome and acute myeloid leukemia) in the patient group treated with dexrazoxane manifested a threefold increase compared with controls, which researchers documented in two randomized studies.<xref ref-type="bibr" rid="article-38183.r13">[13]</xref><xref ref-type="bibr" rid="article-38183.r14">[14]</xref></p>
      </sec>
      <sec id="article-38183.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>According to the FDA, dexrazoxane classifies as a&#x000a0;Category D drug.</p>
        <p>In a study conducted on pregnant mice and rabbits, dexrazoxane dispensation&#x000a0;led to toxicities in embryos and their mothers, as well as embryonal malformation at doses notably&#x000a0;lower than those clinically approved for human use.</p>
        <p>Dexrazoxane use could also lead to infertility in males based on its effects on a repeated dose toxicology research. During this study, rats and dogs received the drug every week for six weeks, in doses that were significantly lower than the specified human dose, with the dogs receiving doses equal to those given to humans. These led to notable cases of testicular atrophy in these test subjects, subsequently attributed to dexrazoxane use.</p>
      </sec>
      <sec id="article-38183.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There are no current guidelines in place for monitoring dexrazoxane.&#x000a0;However, this drug&#x000a0;leads to an acute rise in liver protein production, which may be&#x000a0;indicated by increased liver function tests (LFT), i.e., elevated&#x000a0;alkaline phosphatase and aspartate aminotransferase. Constant monitoring of liver enzymes may be required with the administration of dexrazoxane, keeping in mind that a combination of both dexrazoxane&#x000a0;and doxorubicin&#x000a0;would lead&#x000a0;to a greater increase in&#x000a0;hepatic protein production than dexrazoxane alone.<xref ref-type="bibr" rid="article-38183.r15">[15]</xref></p>
      </sec>
      <sec id="article-38183.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no data on toxicity&#x000a0;in the trials of dexrazoxane,&#x000a0;and no known antidote for a reversal exists in the literature.</p>
        <p>In cases of a suspected overdose, management using good supportive care is advisable. These interventions include targeting areas such as infection treatment and control and fluid management, with regular preservation of nutritional requirements.</p>
      </sec>
      <sec id="article-38183.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dexrazoxane is approved clinically for anthracycline-induced cardiotoxicity (reducing the incidence of congestive heart failure and LVEF dysfunction) and extravasation. This drug is only recommended for use intravenously. Healthcare providers comprising of physicians (ranging from the patient's primary care provider to the oncologist as well a psychologist to deal with any form of mental illness the patient could be going through), nurses, and pharmacists, need to be cognizant of the most common side effects&#x000a0;of this drug which&#x000a0;is myelosuppression and work together to assess dosage of this drug, adjusting doses if and when&#x000a0;necessary to combat adverse consequences seen with myelosuppression, monitor&#x000a0;hematological function,&#x000a0;and tackle any early signs of infection or bleeding. It is also critical to note that dexrazoxane does not completely improve cardiac dysfunction associated with the use of anthracyclines; hence, constant monitoring of heart function should be advised.</p>
        <p>It is also important to get&#x000a0;a&#x000a0;cardio-oncologist specialist involved&#x000a0;when heart failure or a significant decline of left ventricular ejection fraction (LVEF) occurs during chemotherapy. This assistance is critical for careful decision-making regarding&#x000a0;further exposure to cardiotoxic cancer treatment.</p>
        <p>Oncology nurses will be administering this drug in most cases&#x000a0;and need to be conversant&#x000a0;with the adverse effects, which could mimic those seen with anthracyclines, reporting any issues to the physician team&#x000a0;as well as assessing the patient's vitals and injection sites for any signs of inflammation. Patients should be made aware of the adverse reaction seen with dexrazoxane and advised to report any changes noted as soon as possible.&#x000a0;</p>
        <p>Their obstetrician should also counsel patients on pregnancy planning and prevention, as this medication is a known teratogen and can cause fetal harm. Female patients should use effective contraception during treatment.</p>
        <p>It is unknown if dexrazoxane is secreted in breast milk and has any effect on milk production or the breastfed infant. Due to the unknown nature of this drug on milk production or secretion, women should&#x000a0;halt&#x000a0;breastfeeding while on dexrazoxane therapy and for two weeks after the last dose.</p>
      </sec>
      <sec id="article-38183.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38183&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38183">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38183/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38183">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38183.s11">
        <title>References</title>
        <ref id="article-38183.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiseman</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.</article-title>
            <source>Drugs</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>385</fpage>
            <page-range>385-403</page-range>
            <pub-id pub-id-type="pmid">9777314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cvetkovi&#x00107;</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.</article-title>
            <source>Drugs</source>
            <year>2005</year>
            <volume>65</volume>
            <issue>7</issue>
            <fpage>1005</fpage>
            <page-range>1005-24</page-range>
            <pub-id pub-id-type="pmid">15892593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipshultz</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Exposure to anthracyclines during childhood causes cardiac injury.</article-title>
            <source>Semin Oncol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>3 Suppl 8</issue>
            <fpage>S8</fpage>
            <page-range>S8-14</page-range>
            <pub-id pub-id-type="pmid">16781284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langer</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Dexrazoxane for the treatment of chemotherapy-related side effects.</article-title>
            <source>Cancer Manag Res</source>
            <year>2014</year>
            <volume>6</volume>
            <fpage>357</fpage>
            <page-range>357-63</page-range>
            <pub-id pub-id-type="pmid">25246808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease.</article-title>
            <source>Neuropharmacology</source>
            <year>2019</year>
            <month>Dec</month>
            <day>01</day>
            <volume>160</volume>
            <fpage>107758</fpage>
            <pub-id pub-id-type="pmid">31494143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasinoff</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Kuschak</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Yalowich</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Creighton</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).</article-title>
            <source>Biochem Pharmacol</source>
            <year>1995</year>
            <month>Sep</month>
            <day>28</day>
            <volume>50</volume>
            <issue>7</issue>
            <fpage>953</fpage>
            <page-range>953-8</page-range>
            <pub-id pub-id-type="pmid">7575679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cruz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duarte-Rodrigues</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Campelo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cardiotoxicity in anthracycline therapy: Prevention strategies.</article-title>
            <source>Rev Port Cardiol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>359</fpage>
            <page-range>359-71</page-range>
            <pub-id pub-id-type="pmid">27255173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nitiss</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Targeting DNA topoisomerase II in cancer chemotherapy.</article-title>
            <source>Nat Rev Cancer</source>
            <year>2009</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>338</fpage>
            <page-range>338-50</page-range>
            <pub-id pub-id-type="pmid">19377506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ruan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Dou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>2020</year>
            <month>Feb</month>
            <day>26</day>
            <volume>523</volume>
            <issue>1</issue>
            <fpage>140</fpage>
            <page-range>140-146</page-range>
            <pub-id pub-id-type="pmid">31837803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Espi&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Llombart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monnier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Stahalova</surname>
                <given-names>V</given-names>
              </name>
              <collab>Dexrazoxane Study Group</collab>
            </person-group>
            <article-title>Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.</article-title>
            <source>Ann Oncol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>614</fpage>
            <page-range>614-22</page-range>
            <pub-id pub-id-type="pmid">16423847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vogel</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Gorowski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Davila</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eisenberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kosinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Savaraj</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.</article-title>
            <source>Invest New Drugs</source>
            <year>1987</year>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-98</page-range>
            <pub-id pub-id-type="pmid">3115912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holcenberg</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Tutsch</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Earhart</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Ungerleider</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Kamen</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Gribble</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Glaubiger</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults.</article-title>
            <source>Cancer Treat Rep</source>
            <year>1986</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>703</fpage>
            <page-range>703-9</page-range>
            <pub-id pub-id-type="pmid">3089595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salzer</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Devidas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Winick</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pullen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hunger</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Camitta</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.</article-title>
            <source>Leukemia</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>355</fpage>
            <page-range>355-70</page-range>
            <pub-id pub-id-type="pmid">20016527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tebbi</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Villaluna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Alarcon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Constine</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Mendenhall</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Sposto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chauvenet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.</article-title>
            <source>J Clin Oncol</source>
            <year>2007</year>
            <month>Feb</month>
            <day>10</day>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>493</fpage>
            <page-range>493-500</page-range>
            <pub-id pub-id-type="pmid">17290056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38183.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sherwood</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Preedy</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Acute dosage with dexrazoxane, but not doxorubicin, is associated with increased rates of hepatic protein synthesis in vivo.</article-title>
            <source>Toxicol Pathol</source>
            <year>2001</year>
            <season>Nov-Dec</season>
            <volume>29</volume>
            <issue>6</issue>
            <fpage>591</fpage>
            <page-range>591-9</page-range>
            <pub-id pub-id-type="pmid">11794374</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
